Breakthrough Invasive Fungal Infections in Patients With Hematologic Malignancy (HM) and Hematopoietic Cell Transplantation (HCT) Receiving Isavuconazole for Empiric or Directed Antifungal Therapy

Abstract

Methods. All patients with HM and HCT recipients who received >7 days of empiric or specific therapy (for suspected IFI) with ISA were evaluated for breakthrough invasive fungal infections (br-IFI). The cases were identified from microbiology database, and classified as proven or probable per EORTC/MSG definitions. ISA usage was obtained from pharmacy database (between May 2015 and March 2016). Information was collected for: demographics, underlying diagnosis, disease status, HCT or non-HCT, graft versus host disease (GvHD), duration of ISA use prior to diagnosis of br-IFI, and type of fungal organism causing the breakthrough infection.